12-month Safety and Efficacy Outcomes of a Standalone Trabecular Bypass Device Save Sight Registries 12-month Safety and Efficacy Outcomes of a Standalone Trabecular Bypass Device Read More »
Outcomes and Baseline Predictors of Failure in Primary Standalone Xen45 Gel Stent versus Trabeculectomy for Glaucoma Save Sight Registries Outcomes and Baseline Predictors of Failure in Primary Standalone Xen45 Gel Stent versus Trabeculectomy for Glaucoma Read More »
Outliers of Treatment Frequency in Retinal Vein Occlusion: 24-Month Comparative Analysis of Fight Retinal Blindness! Practitioners Save Sight Registries Outliers of Treatment Frequency in Retinal Vein Occlusion: 24-Month Comparative Analysis of Fight Retinal Blindness! Practitioners Read More »
Impact of cataract surgery on patients receiving intravitreal therapy for retinal vein occlusion Save Sight Registries Impact of cataract surgery on patients receiving intravitreal therapy for retinal vein occlusion Read More »
12-month Safety and Efficacy Outcomes of a Standalone Trabecular Bypass Device Save Sight Registries 12-month Safety and Efficacy Outcomes of a Standalone Trabecular Bypass Device Read More »
The Fight Inherited Retinal Blindness! Project: A new treatment outcome and natural history registry for inherited retinal disease Save Sight Registries The Fight Inherited Retinal Blindness! Project: A new treatment outcome and natural history registry for inherited retinal disease Read More »
Efficient capture of dry eye data from the real world: The Save Sight Dry Eye Registry Save Sight Registries Efficient capture of dry eye data from the real world: The Save Sight Dry Eye Registry Read More »
Longitudinal outcomes of iStent inject with cataract surgery compared to cataract surgery alone: real-world data from the Fight Glaucoma Blindness registry Save Sight Registries Longitudinal outcomes of iStent inject with cataract surgery compared to cataract surgery alone: real-world data from the Fight Glaucoma Blindness registry Read More »
Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice Save Sight Registries Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice Read More »
Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study Save Sight Registries Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study Read More »
One-year anti-VEGF therapy outcomes in diabetic macular edema based on treatment intensity: Data from the FRB! registry Save Sight Registries One-year anti-VEGF therapy outcomes in diabetic macular edema based on treatment intensity: Data from the FRB! registry Read More »
European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice: Data from the Fight Retinal Blindness! Registry Save Sight Registries European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice: Data from the Fight Retinal Blindness! Registry Read More »
